Public scientific infrastructure (data repositories, software ecosystems, foundational research programs, and open-source tools) forms the backbone of biomedical innovation. But recent and ongoing shifts in U.S. federal funding have introduced significant instability, with consequences that ripple from early academic discovery to startup formation, venture investment, pharma R&D, and global data access. These changes threaten not only scientific progress, but also U.S. competitiveness, innovation pipelines, and the reproducibility of AI/ML models that increasingly rely on publicly funded datasets and code.
This session convenes diverse voices across the biomedical R&D ecosystem to examine how funding disruptions are reshaping discovery, development, and long-term innovation and what each sector believes is needed to maintain a stable scientific future. We open with global survey results from the Global Alliance for Open Science (GAFOS), founded at the 2025 Bio-IT World Conference & Expo. With input from more than 170 professionals across academia, biotech, pharma, government, and nonprofits, the survey reveals community-wide concern, emerging risks, and real-world challenges as core public data and software resources become increasingly unstable.
The discussion then expands beyond the survey to include perspectives from early-stage academic researchers who rely on NIH/NSF grants; seed- and pre-seed founders generating the data needed to attract private investment; venture capital groups assessing risk in a weakening public infrastructure environment; pharma and techbio teams dependent on public datasets and open tools for drug discovery, diagnostics, and ML model development; and policy and regulatory experts evaluating the long-term consequences of reduced public investment on U.S. innovation leadership.
Independent community initiatives, including GAFOS and international organizations engaged in mirroring, redundancy, and policy advocacy, will also share how the global community is responding to emerging risks.
Attendees will leave with a data-driven understanding of the challenges ahead, a cross-sector view of what is at stake, and actionable strategies the Bio-IT community can advance to safeguard the scientific infrastructure upon which biomedical innovation depends.